These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

179 related items for PubMed ID: 12806587

  • 1. Angiotensin II receptor blockers and cardiovascular outcomes: what does the future hold?
    Weber MA.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):62-73. PubMed ID: 12806587
    [Abstract] [Full Text] [Related]

  • 2. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 3. Hypertension mega-trials with cardiovascular end points: effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
    Kjeldsen SE, Julius S.
    Am Heart J; 2004 Nov; 148(5):747-54. PubMed ID: 15523303
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
    Grothusen A, Divchev D, Luchtefeld M, Schieffer B.
    Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
    [Abstract] [Full Text] [Related]

  • 5. Have angiotensin receptor blockers lived up to expectations?
    Fitchett D.
    Can J Cardiol; 2005 May 15; 21(7):569-75. PubMed ID: 15940354
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II receptor blockers and cardiovascular outcomes: the evidence now and in the future.
    Weber M.
    J Renin Angiotensin Aldosterone Syst; 2001 Sep 15; 2 Suppl 2():S12-6. PubMed ID: 11881103
    [Abstract] [Full Text] [Related]

  • 7. Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.
    Epstein BJ, Gums JG.
    Ann Pharmacother; 2005 Mar 15; 39(3):470-80. PubMed ID: 15701766
    [Abstract] [Full Text] [Related]

  • 8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z, Armaly Z, Nakhoul F, Hoffman A.
    Harefuah; 2008 Jun 15; 147(6):536-42, 573. PubMed ID: 18693632
    [Abstract] [Full Text] [Related]

  • 9. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM.
    Acta Diabetol; 2005 Apr 15; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [Abstract] [Full Text] [Related]

  • 10. The biochemical pharmacology of renin inhibitors: implications for translational medicine in hypertension, diabetic nephropathy and heart failure: expectations and reality.
    Abassi Z, Winaver J, Feuerstein GZ.
    Biochem Pharmacol; 2009 Oct 15; 78(8):933-40. PubMed ID: 19477166
    [Abstract] [Full Text] [Related]

  • 11. Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.
    Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.
    Expert Rev Cardiovasc Ther; 2008 Jun 15; 6(5):759-71. PubMed ID: 18510491
    [Abstract] [Full Text] [Related]

  • 12. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K.
    Vnitr Lek; 2007 Apr 15; 53(4):364-70. PubMed ID: 17578167
    [Abstract] [Full Text] [Related]

  • 13. Blocking the renin-angiotensin system: dual- versus mono-therapy.
    Ravandi A, Teo KK.
    Expert Rev Cardiovasc Ther; 2009 Jun 15; 7(6):667-74. PubMed ID: 19505282
    [Abstract] [Full Text] [Related]

  • 14. Angiotensin-converting enzyme inhibitors (ACEIs), not angiotensin receptor blockers (ARBs), are preferred and effective mode of therapy in high cardiovascular risk patients.
    Vijan SG.
    J Indian Med Assoc; 2009 Mar 15; 107(3):178-82. PubMed ID: 19810392
    [Abstract] [Full Text] [Related]

  • 15. ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?
    Ruilope LM, Segura J, Schiffrin EL.
    J Renin Angiotensin Aldosterone Syst; 2003 Jun 15; 4(2):74-9. PubMed ID: 12806588
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED, Preddie DC.
    Ethn Dis; 2002 Jun 15; 12(4):S3-49-52. PubMed ID: 12477155
    [Abstract] [Full Text] [Related]

  • 17. The cardiovascular continuum and renin-angiotensin-aldosterone system blockade.
    Dzau V.
    J Hypertens Suppl; 2005 Apr 15; 23(1):S9-17. PubMed ID: 15821452
    [Abstract] [Full Text] [Related]

  • 18. Will more complete inhibition of the RAAS with angiotensin receptor blockade improve survival following myocardial infarction?
    Pfeffer MA.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun 15; 1(2 Suppl):S41-3. PubMed ID: 17199221
    [Abstract] [Full Text] [Related]

  • 19. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C, Croce G, Desideri G.
    Adv Ther; 2008 Apr 15; 25(4):300-20. PubMed ID: 18449492
    [Abstract] [Full Text] [Related]

  • 20. Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers.
    Nickenig G, Ostergren J, Struijker-Boudier H.
    J Renin Angiotensin Aldosterone Syst; 2006 Jun 15; 7 Suppl 1():S1-7. PubMed ID: 16969748
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.